GH Research (GHRS) Shares Outstanding (2020 - 2026)
GH Research (GHRS) posted quarterly Shares Outstanding (Entity) of $24.4 million for Q4 2025, up 17.33% year-over-year from $20.8 million in Q4 2024, and down 1.59% quarter-over-quarter from $24.8 million in Q3 2025.
Analysis
GH Research (GHRS) Shares Outstanding (2020 - 2026) Analysis & Trends
GH Research's Shares Outstanding (Entity) history runs 6 years deep, the most recent figure standing at $24.4 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 17.33% year-over-year to $24.4 million; the TTM figure through Dec 2025 stood at $24.4 million (up 17.33% YoY), while the FY2025 annual figure was $24.4 million, up 17.33% from the prior year.
- Shares Outstanding (Entity) for Q4 2025 stood at $24.4 million, down from $24.8 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $24.8 million in Q3 2025, with the low at $17.5 million in Q4 2021.
- The 5-year median for Shares Outstanding (Entity) is $20.8 million (2023), against an average of $21.5 million.
- The sharpest annual moves came in 2021 and 2023: Shares Outstanding (Entity) soared 54.03% in 2021, then changed 0.0% in 2023.
- GH Research's Shares Outstanding (Entity) stood at $17.5 million in 2021, then increased by 19.09% to $20.8 million in 2022, then climbed by 0.0% to $20.8 million in 2023, then advanced by 0.01% to $20.8 million in 2024, then grew by 17.33% to $24.4 million in 2025.
- Business Quant data shows GHRS's Shares Outstanding (Entity) at $24.4 million in Q4 2025, $24.8 million in Q3 2025, and $24.8 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 217.35 Mn |
| 10 | GH Research | 1.71 Bn | 1.35 Bn | - | 61.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.04 Mn |
| Mar 31, 2026 | 61.04 Mn |
| Dec 31, 2025 | 61.04 Mn |
| Sep 30, 2025 | 52.03 Mn |
| Jun 30, 2025 | 52.03 Mn |
| Mar 31, 2025 | 52.03 Mn |
| Dec 31, 2024 | 52.03 Mn |
| Sep 30, 2024 | 52.02 Mn |
| Jun 30, 2024 | 52.02 Mn |
| Mar 31, 2024 | 52.02 Mn |
| Dec 31, 2023 | 52.02 Mn |
| Sep 30, 2023 | 52.02 Mn |
| Jun 30, 2023 | 52.02 Mn |
| Mar 31, 2023 | 52.02 Mn |
| Dec 31, 2022 | 52.02 Mn |
| Sep 30, 2022 | 43.68 Mn |
| Jun 30, 2022 | 43.68 Mn |
| Mar 31, 2022 | 43.68 Mn |
| Dec 31, 2021 | 43.68 Mn |
| Sep 30, 2021 | 28.36 Mn |